30-Second Takeaway
- Population genetic testing identifies high-risk women missed by clinical and polygenic risk models.
- Proficiency-based progression training substantially reduces procedural errors when criteria are strictly applied.
- CDSMP yields modest, persistent improvements in pain, depression, sleep, and fatigue at six months.
Week ending June 6, 2026
MedBrevia Grand Rounds: Selected preventive medicine evidence briefs
Stroke Riskometer app did not improve Life's Simple 7 at six months
In a phase III RCT of 862 adults aged 35–75 with ≥2 stroke risk factors, access to the Stroke Riskometer app did not change mean Life's Simple 7 score at six months (mean difference 0.03; 95% CI, -0.19 to 0.25; P=0.788). Per-protocol analyses and subgroup checks were similar and showed no consistent improvements in individual risk factors. The intervention produced a borderline increase in physical activity (MET-minutes/week difference ~313; P=0.052) but no other clinically meaningful changes. Applicability is to smartphone-owning adults without cardiovascular disease; the app alone is not practice-changing for short-term risk-factor modification.
Population pathogenic-variant testing changes breast screening assignments
In a WISDOM secondary analysis of 712 women with pathogenic variants, most PV carriers would not have been flagged for high-risk screening by clinical risk or clinical-plus-polygenic models. Among 232 high-penetrance PV carriers, only 0.9% would have been assigned high-risk screening by clinical-plus-polygenic risk. Large proportions of PV carriers aged 40–49 and 50–74 would have been recommended later or less-intensive screening without PV knowledge. Conclusion: adding PV testing to population risk assessment materially alters screening recommendations and uncovers high-risk individuals missed by other models.
CDSMP yields modest, sustained symptom improvements at six months
This systematic review/meta-analysis (20 studies) found small but persistent reductions at six months in pain (mean difference 0.53), depressive symptoms (1.47 PHQ-9 points), fatigue (0.46), and sleep problems (0.57). Effects were consistent across countries and among adults with common chronic diseases such as hypertension, heart disease, and stroke. Benefits are modest in size but durable to six months and relevant where nonpharmacologic self-management is prioritized. Implementation barriers noted across studies include funding, recruitment, and retention.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.